No Picture

Little biotech’s stock flatlines as its followup attempt at a depression drug trial win ends in another defeat

You can add one more depression drug trial to the scrap heap of failed clinical explorations.
VistaGen followed its spring failure for AV-101 as a monotherapy with a followup defeat using the therapy as an adjunctive treatment for major depression, add… […]